GLP-1
-
ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss 【Product for Licensing】
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Musk’s Hobby Also Sparks a Boom for WuXi AppTec!
For more reports, please follow DrugTimes
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
【重磅消息】欧盟委员会无条件批准了Novo Holdings对Catalent的165亿美元收购计划
药时代将持续跟踪报道这一重要交易的进展，欢迎广大朋友们关注药时代，获取最新资讯！
-
NASDAQ-listed companies are looking for obesity drugs with the potential for weight loss and muscle gain
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
GLP-1触发的 “连招”，何止医美？
GLP-1已成当下MNC研发管线的标配。 除已有大热产品上市的诺和诺德、礼来外，近期包括罗氏、辉瑞也接连宣布其在研GLP-1产品的好消息。 2024年7月15日，国外媒体ENDPO…
-
Try again! Pfizer ‘revives’ its oral GLP-1RA
DrugTimes will present more reports. Please stay tuned
-
What is the Current Landscape of Obesity Drug Development in China?
These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment
-
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives
-
降糖“潜力股”，礼来GIP / GLP-1双重激动剂显著降低2型糖尿病患者血糖水平和体重
随着人们的物质生活逐渐丰富，糖尿病这种过去的“富贵病”的发病率也日渐上升。慢性病虽不至于导致病人短时间内去世，然而长久的折磨无疑会对病患自身和家人的生活质量造成极为不良影响。另一方…
